Table 1.

Patient #	Drug(s)	Total # of Cycles	Adherence Statement Response	Adverse Events*	Best Tumor Response
1	capecitabine	2	“always or almost always”	Cycle 2: thrombosis (grade 4); anorexia, dehydration, nausea, vomiting, diarrhea, muscle weakness (grade 3)	stable
2	capecitabine (crossed over to both drugs after cycle 9 for 3 cycles)	9	Cycle 1: “usually” Cycles 2–9: “always or almost always”	none	stable
3	capecitabine (crossed over to both drugs after cycle 1 for 1 cycle)	1	“always or almost always”	none	progression
4	capecitabine	2	“always or almost always”	Cycles 1 and 2: diarrhea (grade 3)	progression
5	capecitabine	2	“always or almost always”	Cycle 2: fatigue (grade 3)	stable
6	capecitabine	12	“always or almost always”	Cycle 2 and 6: hand/foot syndrome (grade 3); Cycle 10: diarrhea (grade 3); Cycle 12: thrombosis (grade 3)	stable
7	capecitabine sunitinib	1	not available	Cycle 1: mucositis (grade 3); neutropenia (grade 4); febrile neutropenia (grade 3)	not available
8	capecitabine sunitinib	10	“always or almost always”	Cycle 1: gastrointestinal bleeding and anemia on warfarin (grade 3) Cycle 10: neutropenia and anemia (grade 3)	partial response
9	capecitabine sunitinib	1	“always or almost always”	Cycle 1: vomiting (grade 3); esophageal pain (grade 4)	progression
10	capecitabine sunitinib	2	Cycle 1: “rarely” Cycle 2: “always or almost always”	Cycle 1: anorexia, dehydration, gastritis, gastrointestinal anastomotic leak, muscle weakness (all grade 3) Cycle 2: fatigue, anorexia, gastritis (all grade 3)	progression
11	capecitabine sunitinib	3	“always or almost always”	Cycle 1: hand foot syndrome, rash, mucositis (all grade 3)	stable
12	capecitabine sunitinib	8	“always or almost always”	Cycle 5: pneumonitis (grade 3)	partial response

^*Only grade 3 or worse adverse were reported in this trial.